Shock wave transdermal delivery hydrogel microneedle device

Through the shock wave transdermal drug delivery hydrogel microneedle device, the combination of hydrogel microneedle assembly and shock wave source is used to solve the problem of pain and low absorption efficiency of drug application in bone muscle disease treatment, and achieve painless and efficient drugs Improved delivery and treatment effects.

CN221950437UActive Publication Date: 2024-11-05CHINA JAPAN FRIENDSHIP HOSPITAL
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202322814045.X
Authority / Receiving Office
CN · China
Patent Type
Utility models(China)
Current Assignee / Owner
Filing Date
2023-10-19
Publication Date
2024-11-05
Estimated Expiration
2033-10-19

AI Technical Summary

Technical Problem

The prior art has problems such as pain in the treatment of bone muscle diseases, difficulty in drug use in drug use, first pass elimination and low local concentrations, and the low toughness and non-degradability of traditional microneedle materials bring additional risks.

Method used

A shock wave transdermal drug delivery hydrogel microneedle device is designed, including a hydrogel microneedle assembly and a shock wave source. The hydrogel microneedle assembly is closely attached to the skin through a hydrogel microneedle patch and a plastic film to provide the dermal channel and use shock wave sources to generate mechanical stress to promote drug absorption and treatment efficiency.

Benefits of technology

Under the premise of painlessness, the local delivery efficiency of the drug in the diseased area is improved, the factors that reduce the drug utilization rate are reduced, the efficacy and utilization rate of drug treatment of bone muscle diseases are improved, and the treatment experience and compliance of patients are improved.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN221950437U_ABST
    Figure CN221950437U_ABST
Patent Text Reader

Abstract

The utility model provides a shock wave transdermal delivery hydrogel microneedle device, which relates to the technical field of medical instruments and comprises a hydrogel microneedle component and a shock wave source. The hydrogel microneedle assembly can be tightly attached to the skin of an affected part of a patient and is used for enabling the medicine to directly permeate into a corium layer of the skin; the shock wave source is tightly attached to the hydrogel microneedle assembly and used for continuously emitting shock waves to the affected part of the patient. The hydrogel microneedle assembly comprises: a hydrogel microneedle patch; the hydrogel microneedle patch is integrally prepared from a hydrogel material and is used for providing a percutaneous channel through which a medicine directly permeates into a corium layer of skin and guiding shock waves to directly enter subcutaneous skin; according to the utility model, on the premise of no pain, the medicine is locally delivered to a diseased part within a certain range, and meanwhile, factors such as first-pass elimination and skin epidermis which reduce the medicine utilization rate are avoided, so that the medicine treatment effect and the medicine utilization rate of bone and muscle diseases are improved, the treatment experience of a patient is improved, and the compliance of the patient is improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The utility model relates to the technical field of medical devices, in particular to a shock wave transdermal drug delivery hydrogel microneedle device. Background Art

[0002] Extracorporeal shock wave (ESW), also known as extracorporeal shock wave, is a discontinuous pulse mechanical wave with low frequency, short period and high energy. Due to the different propagation speeds and acoustic impedances of shock waves in different media, it produces energy gradient differences and torsional tension on the contact surface with the material. The shock wave generates mechanical stress, piezoelectric effect and cavitation effect through compressive stress and tensile stress in the conduction process, acting on local tissue cells, and exerting effects through "mechanical force-electrochemical-biological effect".

[0003] Studies have shown that the mechanism of extracorporeal shock wave therapy (ESWT) in the treatment of bone and muscle diseases is complex. On the one hand, the mechanical stress and cavitation effect of shock waves can promote the lysis of sclerotic bones, increase cell permeability, loosen soft tissues, and dredge blocked blood vessels, thereby improving local microcirculation. On the other hand, shock waves act on cells or extracellular matrices, initiate nuclear reactions through signal transduction pathways, and have biological effects on living tissues at the cellular and molecular levels, inducing the transformation and release of cytokines, promoting local bone tissue and blood vessel regeneration, and improving bone repair. At the same time, shock waves block pain nerve receptors by inhibiting nerve ending cells, changing the frequency of pain receptor reception, and inhibiting the release of pain-related transmitters, thereby improving patients' local pain.

[0004] Compared with traditional treatment methods, extracorporeal shock wave therapy has the advantages of being non-invasive, having few side effects, adjustable stimulation intensity, and low treatment cost. In recent years, it has been widely used in the treatment of musculoskeletal diseases. Many studies have shown that ESWT has demonstrated a practical and reliable therapeutic effect in clinical application.

[0005] Microneedles (MNs) are cone-like devices with a length of less than 1000 μm. They can form a percutaneous channel within a certain period of time, cross the epidermis, and promote the direct penetration of drugs into the subcutaneous layer or into the blood circulation. Depending on the application scenario, common carriers of microneedles include pens, rollers, patches, etc. Traditional microneedles are made of metal, silicon, etc. Due to the limitations of the material itself (low toughness, non-degradability), it brings additional risks to treatment.

[0006] At present, various polymer materials are widely used in the design and manufacture of new microneedles due to their excellent designability. Their biodegradability and biocompatibility can make up for the shortcomings (residues) of traditional materials. Through targeted design of materials, the mechanical properties and solubility properties of the needle body can be controlled, and then functions such as drug controlled release can be achieved. Common polymer materials include hyaluronic acid, polylactic acid, etc. Among them, polylactic acid microneedles have stronger toughness (fracture resistance) than the aforementioned traditional microneedles while having biodegradability and biocompatibility. Soluble microneedles represented by materials such as hyaluronic acid, polyethylene glycol, and polyvinyl alcohol absorb interstitial fluid and dissolve after piercing the subcutaneous tissue, thereby releasing the loaded drugs.

[0007] At present, a variety of musculoskeletal diseases can be treated with drug-assisted treatment; for example, plantar fasciitis and frozen shoulder can be treated with local application of non-steroidal anti-inflammatory drugs and corticosteroids. At present, the main methods of medication are local injection, external application or patch use. The former causes obvious pain during use and has a limited scope of drug application; the latter two are difficult for drugs to enter the subcutaneous tissue due to the presence of the epidermis, affecting the effectiveness and utilization of the medication. Similarly, in the treatment of diseases that require oral medication, such as femoral head necrosis, some drugs that require oral administration have problems with first-pass elimination and low local concentration. Utility Model Content

[0008] The purpose of the utility model is to provide a shock wave transdermal drug delivery hydrogel microneedle device to solve at least one of the above technical problems existing in the prior art.

[0009] In order to solve the above technical problems, the utility model provides a shock wave transdermal drug delivery hydrogel microneedle device, comprising: a hydrogel microneedle assembly and a shock wave source;

[0010] The hydrogel microneedle assembly can be closely attached to the affected skin of the patient, and is used to provide a transdermal channel, so that the drug can pass through the epidermis layer of the skin and directly penetrate into the dermis layer of the skin;

[0011] The shock wave source is closely attached to the hydrogel microneedle assembly when treating the affected part, and is used to continuously emit shock waves to the affected part of the patient, thereby treating the affected part of the patient using extracorporeal shock wave therapy.

[0012] Extracorporeal shock wave therapy can unclog blocked capillaries and improve microcirculation, while loosening soft tissues and increasing cell permeability, thereby promoting the body's absorption of drugs and improving drug delivery efficiency. The mechanical stress generated by extracorporeal shock wave therapy can further promote the passage of drugs through the percutaneous channel and improve the drug delivery efficiency of the device.

[0013] Furthermore, the shock wave source is usually a shock wave probe.

[0014] Further, the hydrogel microneedle assembly comprises: a hydrogel microneedle patch and a plastic film;

[0015] The hydrogel microneedle patch is made of an integrated hydrogel material and has high mechanical strength and dissolution resistance.

[0016] On the one hand, the hydrogel microneedle patch provides a transdermal channel for drugs to directly penetrate into the dermis of the skin, helping the drugs to pass through the epidermis of the skin and directly penetrate into the blood vessels or tissues of the dermis of the skin, thereby effectively reducing the patient's pain; on the other hand, the hydrogel microneedle patch acts as a medium to guide the shock wave directly into the subcutaneous tissue, thereby improving the treatment efficiency by changing the shock wave conduction medium.

[0017] The plastic film is arranged on the back of the hydrogel microneedle patch and is used to fix the hydrogel microneedle patch on the affected skin of the patient.

[0018] Furthermore, the shape of the plastic film is the same as that of the hydrogel microneedle patch, and the area is larger than that of the hydrogel microneedle patch.

[0019] Further, the hydrogel microneedle patch comprises: a backing layer and a microneedle array;

[0020] The backing layer is a flexible cushion with a smooth surface, which can be closely attached to the affected skin of the patient and the shock wave probe, and is used to fill the gap between the affected skin of the patient and the shock wave probe;

[0021] The front side of the backing layer is provided with a plurality of microneedle arrays arranged at equal intervals and capable of piercing the skin. The microneedle array is a rectangular array composed of a plurality of microneedles arranged at equal intervals.

[0022] After the microneedle array pierces the skin, the hydrogel microneedle patch absorbs cell tissue fluid and softens, and the toughness of the hydrogel microneedle patch increases accordingly, so that it can withstand the mechanical stress of the shock wave.

[0023] After softening, the backing layer can replace the coupling agent, eliminate the air between the skin and the shock wave probe, reduce the acoustic resistance, and the shock wave probe can slide smoothly on the back of the backing layer. Therefore, there is no need to apply coupling agent during treatment, thereby improving the patient's treatment experience.

[0024] The backing layer is a barrier between the affected skin of the patient and the shock wave probe, thereby avoiding direct contact between the patient and the doctor and reducing the risk of infection.

[0025] Furthermore, the backing layer is usually 2000-5000 μm thick and 5*5 cm in size, depending on the application site and the shock wave probe. 2 ~10*10cm2 .

[0026] Furthermore, the spacing between the microneedle arrays is greater than the spacing between the microneedles.

[0027] Furthermore, the spacing between the microneedle arrays is generally 2000-5000 μm, depending on the size of the hydrogel microneedle patch.

[0028] Furthermore, the spacing between the microneedles is generally 500-800 μm depending on the application site.

[0029] Furthermore, the size of the microneedle on the hydrogel microneedle patch is usually 1*1 cm. 2 ~2.5*2.5cm 2 .

[0030] Furthermore, the backing layer is also provided with a plurality of bending regions, and the bending regions are arranged between adjacent microneedle arrays for bending the hydrogel microneedle patch.

[0031] Furthermore, the microneedle is a cone, which is arranged on the front side of the backing layer and is used to pierce the epidermis of the skin to create a transdermal channel.

[0032] The microneedle is made of hydrogel, and the cross-linking of the polymer can enhance the penetration performance of the microneedle. At the same time, the anti-dissolution property of the hydrogel can enable the microneedle to maintain the transdermal channel created by the microneedle after piercing the epidermis of the skin.

[0033] Furthermore, the diameter of the microneedle channel is smaller than the distance between the microneedles.

[0034] Furthermore, the diameter of the microneedle is usually 50 to 200 μm depending on the application site.

[0035] Furthermore, the height of the microneedle is generally 200 to 800 μm depending on the application site.

[0036] Furthermore, a plurality of tiny holes are arranged in the microneedle to further allow the drug to penetrate into the dermis of the skin.

[0037] Furthermore, the plastic film is provided with an easy-tear strip, which is arranged in the middle of the plastic film and is used to tear the plastic film to expose the back side of the hydrogel microneedle patch, so that the shock wave probe is attached to the back side of the backing layer of the hydrogel microneedle patch for shock wave therapy.

[0038] Furthermore, the hydrogel microneedle assembly also includes a protective film, which is arranged on the front side of the hydrogel microneedle patch to prevent the front side of the hydrogel microneedle patch from being contaminated.

[0039] Furthermore, the hydrogel microneedle assembly also includes a sealing film, which is arranged on the back side of the plastic film and connected to the plastic film at both ends to seal the exposed portion of the back side of the hydrogel microneedle patch.

[0040] Furthermore, an easy-tear line is provided at one end of the closing film, and the easy-tear line is provided at the connection between the closing film and the plastic film, and is used to tear the closing film to expose the plastic film.

[0041] Furthermore, the closure film is also provided with a plurality of fitting strips, which are arranged at the edge of the closure film and are used to make the closure film fit on the affected skin of the patient, thereby sealing the exposed portion of the back side of the hydrogel microneedle patch.

[0042] By adopting the above technical solution, the utility model has the following beneficial effects:

[0043] The utility model provides a shock wave transdermal drug delivery hydrogel microneedle device, which can deliver drugs locally to the diseased part within a certain range without pain, and at the same time bypasses factors that reduce drug utilization such as first-pass elimination and skin epidermis, thereby greatly improving the drug treatment effect and drug utilization of bone and muscle diseases, improving the patient's treatment experience, and improving the patient's compliance. BRIEF DESCRIPTION OF THE DRAWINGS

[0044] In order to more clearly illustrate the specific implementation methods of the utility model or the technical solutions in the prior art, the drawings required for use in the specific implementation methods or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some implementation methods of the utility model. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0045] Figure 1 A schematic diagram of a hydrogel microneedle device for shock wave transdermal drug delivery provided in Example 1 of the utility model;

[0046] Figure 2 for Figure 1 A schematic diagram of the back side of the shock wave transdermal drug delivery hydrogel microneedle device is shown;

[0047] Figure 3 for Figure 1 The shock wave transdermal drug delivery hydrogel microneedle device is shown as a front view after the protective film is torn off;

[0048] Figure 4 for Figure 1 A partial enlarged view of point A shown;

[0049] Figure 5 for Figure 1 Schematic diagram of microneedles of the hydrogel microneedle device for shock wave transdermal drug delivery;

[0050] Figure 6 for Figure 3 A partial enlarged view of point B shown;

[0051] Figure 7 for Figure 1 Schematic diagram of the back of the shock wave transdermal drug delivery hydrogel microneedle device after the tear strip is torn off

[0052] Figure 8 for Figure 1 The schematic diagram of the shock wave transdermal drug delivery hydrogel microneedle device in use is shown;

[0053] Fig. 9 A schematic diagram of a hydrogel microneedle device for shock wave transdermal drug delivery provided in Example 2 of the present utility model;

[0054] Fig.10 for Fig. 9 A schematic diagram of the back side of the shock wave transdermal drug delivery hydrogel microneedle device is shown;

[0055] Fig.11 for Fig. 9 The schematic diagram of the front side of the shock wave transdermal drug delivery hydrogel microneedle device after the protective film is torn off;

[0056] Fig.12 for Fig. 9 The local enlarged view of point C shown;

[0057] Fig.13 for Fig. 9 The schematic diagram of the back side of the shock wave transdermal drug delivery hydrogel microneedle device after the tear line is torn off;

[0058] Fig.14 for Fig. 9 The schematic diagram of the back side of the shock wave transdermal drug delivery hydrogel microneedle device after the tear strip is torn off.

[0059] Reference numerals:

[0060] 100-hydrogel microneedle patch; 110-backing layer; 111-bending area; 120-microneedle array; 121-microneedles; 122-micro holes; 200-plastic film; 210-tear strip; 300-protective film; 400-sealing film; 410-tear line; 420-fitting strip. DETAILED DESCRIPTION

[0061] The technical solution of the utility model will be described clearly and completely below in conjunction with the accompanying drawings. Obviously, the described embodiments are part of the embodiments of the utility model, not all of the embodiments. Based on the embodiments of the utility model, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the utility model.

[0062] In the description of the present invention, it should be noted that the terms "center", "upper", "lower", "left", "right", "vertical", "horizontal", "inner", "outer", etc., indicating the orientation or positional relationship, are based on the orientation or positional relationship shown in the drawings, and are only for the convenience of describing the present invention and simplifying the description, rather than indicating or implying that the device or element referred to must have a specific orientation, be constructed and operated in a specific orientation, and therefore cannot be understood as limiting the present invention. In addition, the terms "first", "second", and "third" are used for descriptive purposes only, and cannot be understood as indicating or implying relative importance.

[0063] In the description of the present invention, it should be noted that, unless otherwise clearly specified and limited, the terms "installation", "connection" and "connection" should be understood in a broad sense, for example, it can be a fixed connection, a detachable connection, or an integral connection; it can be a mechanical connection or an electrical connection; it can be a direct connection, or it can be indirectly connected through an intermediate medium, or it can be the internal communication of two components. For ordinary technicians in this field, the specific meanings of the above terms in the present invention can be understood according to specific circumstances.

[0064] The present invention will be further explained below in conjunction with specific implementation methods.

[0065] It should also be noted that the following specific embodiments or specific implementations are a series of optimized settings listed in the present invention to further explain the specific content of the invention, and these settings can be used in combination or in association with each other.

[0066] Example 1

[0067] like Figure 1-8As shown, a shock wave transdermal drug delivery hydrogel microneedle device provided in this embodiment includes: a hydrogel microneedle assembly and a shock wave source; the hydrogel microneedle assembly can fit tightly with the patient's affected skin, and is used to provide a transdermal channel, so that the drug passes through the epidermis of the skin and directly penetrates into the dermis of the skin; the shock wave source is closely attached to the hydrogel microneedle assembly when treating the affected part, and is used to continuously send shock waves to the patient's affected part, so as to treat the patient's affected part using extracorporeal shock wave therapy. Extracorporeal shock wave therapy can dredge blocked capillaries and improve microcirculation, while loosening soft tissues and improving cell permeability, thereby promoting the body's absorption of drugs and improving drug delivery efficiency; the mechanical stress generated by extracorporeal shock wave therapy can further promote the passage of drugs through the transdermal channel and improve the drug delivery efficiency of the device. In this embodiment, the shock wave source uses a shock wave probe.

[0068] Reference Figure 2 , Figure 3 As shown, the hydrogel microneedle assembly includes: a hydrogel microneedle patch 100 and a plastic film 200; the hydrogel microneedle patch 100 is made of an integrated hydrogel material and has high mechanical strength and anti-solubility. On the one hand, the hydrogel microneedle patch 100 provides a transdermal channel for the drug to directly penetrate into the dermis of the skin, helping the drug to pass through the epidermis of the skin and directly penetrate into the blood vessels or tissues of the dermis of the skin, thereby effectively reducing the patient's pain; on the other hand, the hydrogel microneedle patch 100 acts as a medium to guide the shock wave directly into the subcutaneous tissue, and improves the treatment efficiency by changing the shock wave conduction medium. The plastic film 200 is arranged on the back of the hydrogel microneedle patch 100, and is used to fix the hydrogel microneedle patch 100 on the affected skin of the patient.

[0069] Reference Figure 3As shown, the hydrogel microneedle patch 100 includes: a backing layer 110 and a microneedle array 120; the backing layer 110 is a flexible cushion with a smooth surface, which can fit closely with the patient's affected skin and the shock wave probe, and is used to fill the gap between the patient's affected skin and the shock wave probe; the front of the backing layer 110 is provided with four equally spaced microneedle arrays 120 that can penetrate the skin, and each microneedle array 120 is a rectangular array composed of 100 equally spaced microneedles 121. After the microneedle array 120 penetrates the skin, the hydrogel microneedle patch 100 absorbs cell tissue fluid and softens, and the toughness of the hydrogel microneedle patch 100 increases accordingly, and can withstand the mechanical stress of the shock wave. After the backing layer 110 softens, it can replace the coupling agent, eliminate the air between the skin and the shock wave probe, reduce the acoustic resistance, and the shock wave probe can slide smoothly on the back of the backing layer 110. Therefore, there is no need to apply coupling agent during treatment, thereby improving the patient's treatment experience. The backing layer 110 is a barrier between the patient's affected skin and the shock wave probe, avoiding direct contact between the patient and the doctor, and reducing the risk of infection.

[0070] Reference Figure 1 , Figure 3 , Figure 4 As shown, in this embodiment, the thickness of the backing layer 110 is set to 2000 μm, and the size is usually 5*5 cm 2 . More preferably, the spacing between the microneedle arrays 120 is greater than the spacing between the microneedles 121. In this embodiment, the spacing between the microneedle arrays 120 is set to 5000 μm according to the size of the hydrogel microneedle patch 100. The spacing between the microneedles 121 is set to 500 μm. In this embodiment, a microneedle array 120 is 10*10 (pieces), and the range size of the microneedles 121 on the hydrogel microneedle patch 100 is set to 1*1 cm 2 .

[0071] Reference Figure 6 As shown, more preferably, the backing layer 110 is further provided with four bending regions 111 , and the bending regions 111 are provided between adjacent microneedle arrays 120 for bending the hydrogel microneedle patch 100 .

[0072] Reference Figure 5In this embodiment, the microneedle 121 is a cone, which is arranged on the front side of the backing layer 110, and is used to pierce the epidermis of the skin to create a transdermal channel. The microneedle 121 is made of hydrogel, and the cross-linking of the polymer can enhance the penetration performance of the microneedle 121. At the same time, the anti-solubility of the hydrogel can enable the microneedle 121 to maintain the transdermal channel created by the microneedle 121 after piercing the epidermis of the skin. More preferably, the diameter of the microneedle 121 is smaller than the spacing between the microneedles 121. In this embodiment, the diameter of the microneedle 121 is 50μm. The height of the microneedle 121 is 200μm. A number of tiny holes 122 are arranged in the microneedle 121 to further allow the drug to penetrate into the dermis of the skin.

[0073] Reference Figure 2 , Figure 7 As shown, more preferably, the plastic film 200 is provided with an easy-tear strip 210, which is provided in the middle of the plastic film 200 and is used to tear the plastic film 200 to expose the back side of the hydrogel microneedle patch 100, so that the shock wave probe is attached to the back side of the backing layer 110 of the hydrogel microneedle patch 100 for shock wave treatment. The area of ​​the easy-tear strip 210 is larger than the range of the microneedles 121 on the hydrogel microneedle patch 100.

[0074] Reference Figure 1 , Figure 4 As shown, the hydrogel microneedle assembly further includes a protective film 300 , which is disposed on the front side of the hydrogel microneedle patch 100 to prevent the front side of the hydrogel microneedle patch 100 from being contaminated.

[0075] Reference Figure 1-2 , Figure 4 , Figure 7-8 As shown, when using a shock wave transdermal drug delivery hydrogel microneedle device provided in this embodiment, first, expose the affected skin of the patient, and the doctor examines and disinfects the affected area. After the affected area is dry, the doctor applies the liquid medicine or gel-like medicine to be used to the affected skin of the patient. Then, tear off the protective film 300 on the inner side of the hydrogel microneedle assembly, and quickly apply the hydrogel microneedle assembly to the affected skin of the patient. This process requires ensuring that the backing layer 110 of the hydrogel microneedle patch 100 fits well with the skin and the microneedle 121 completely penetrates the skin. Then, the doctor uses the plastic film 200 to fix the hydrogel microneedle patch 100 on the affected skin of the patient. After the hydrogel microneedle patch 100 softens, tear off the tear strip 210, fit the shock wave probe to the back of the backing layer 110 of the hydrogel microneedle patch 100, and start extracorporeal shock wave therapy. After the treatment, the physician removes the hydrogel microneedle assembly to complete the external shock wave therapy.

[0076] The beneficial effects of the utility model are:

[0077] (1) Hydrogel microneedles are used to create percutaneous channels, which, on the one hand, help drugs pass through the epidermis of the skin and directly enter the dermis of the skin without piercing the muscles, effectively avoiding pain; on the other hand, they act as a medium to guide shock waves directly into the subcutaneous tissue, thereby improving the treatment efficiency by changing the shock wave conduction medium;

[0078] (2) The backing layer of the hydrogel microneedle patch absorbs the cell tissue fluid and softens, so that it can fit closely to the skin and the shock wave probe, filling the gap between the two, playing the role of replacing the coupling agent and improving the patient's treatment experience;

[0079] (3) The backing layer forms a certain barrier between the patient's affected skin and the shock wave probe, which reduces the direct contact between the patient and the physician to a certain extent and reduces the risk of infection.

[0080] (4) Make full use of the characteristics of extracorporeal shock wave therapy to dredge blocked capillaries, improve microcirculation, loosen soft tissues, and enhance cell permeability, thereby promoting the body's absorption of drugs and improving the drug delivery efficiency of the shock wave transdermal drug delivery hydrogel microneedle device;

[0081] (5) Make full use of the mechanical stress of extracorporeal shock wave therapy to further promote the passage of drugs through the transdermal channels created by microneedles and improve the drug delivery efficiency of the shock wave transdermal drug delivery hydrogel microneedle device.

[0082] Example 2

[0083] This embodiment is basically the same as Embodiment 1, except that:

[0084] like Figure 9-14 As shown, in this embodiment, the hydrogel microneedle assembly further includes a closing film 400 , which is disposed on the back of the plastic film 200 , with both ends connected to the plastic film 200 , and is used to close the exposed portion of the back of the hydrogel microneedle patch 100 .

[0085] An easy-tear line 410 is disposed at one end of the closing film 400 . The easy-tear line 410 is disposed at the connection between the closing film 400 and the plastic film 200 and is used to tear open the closing film 400 to expose the plastic film 200 .

[0086] The closure film 400 is also provided with four fitting strips 420, which are provided at the edge of the closure film 400 and are used to fit the closure film 400 on the affected skin of the patient, thereby sealing the exposed portion of the back side of the hydrogel microneedle patch 100. In this embodiment, the closure film 400 is provided with four fitting strips 420, which are respectively provided at the four edges of the closure film 400.

[0087] When using a shock wave transdermal drug delivery hydrogel microneedle device provided in this embodiment, first, expose the affected skin of the patient, and the doctor examines and disinfects the affected skin. After the affected area is dry, the doctor applies the liquid medicine or gel-like medicine to be used on the affected skin of the patient. Then, tear off the protective film 300 on the inner side of the hydrogel microneedle assembly, and quickly apply the hydrogel microneedle assembly to the affected skin of the patient. This process requires ensuring that the backing layer 110 of the hydrogel microneedle patch 100 fits well with the skin and the microneedle 121 completely penetrates the skin. Then, the doctor uses the plastic film 200 to fix the hydrogel microneedle patch 100 on the affected skin of the patient. After the hydrogel microneedle patch 100 softens, tear off the easy-tear line 410 to expose the plastic film, then tear off the easy-tear strip 210, fit the shock wave probe to the back of the backing layer 110 of the hydrogel microneedle patch 100, and start extracorporeal shock wave therapy. After the treatment, the physician uses the sealing film 400 to seal the exposed portion of the back of the backing layer 110 of the hydrogel microneedle patch 100 through the adhesive strip 420 to maintain the drug administration for a certain period of time, and the patient removes it by himself after a certain period of time.

[0088] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the utility model, rather than to limit it. Although the utility model has been described in detail with reference to the aforementioned embodiments, ordinary technicians in this field should understand that they can still modify the technical solutions recorded in the aforementioned embodiments, or replace some or all of the technical features therein with equivalents. However, these modifications or replacements do not make the essence of the corresponding technical solution deviate from the scope of the technical solution of the embodiments of the utility model.

Claims

1. A hydrogel microneedle device for shock wave transdermal drug delivery, characterized in that: include: hydrogel microneedle assembly and shock wave source; The hydrogel microneedle assembly can be closely attached to the affected skin of the patient, so as to allow the drug to directly penetrate into the dermis of the skin; The shock wave source is closely attached to the hydrogel microneedle assembly and is used to continuously send shock waves to the affected part of the patient; The hydrogel microneedle assembly comprises: a hydrogel microneedle patch and a plastic film; The hydrogel microneedle patch is made of an integrated hydrogel material, and is used to provide a transdermal channel for drugs to directly penetrate into the dermis of the skin, and to guide shock waves directly into the subcutaneous layer; The plastic film is arranged on the back of the hydrogel microneedle patch and is used to fix the hydrogel microneedle patch on the affected skin of the patient.

2. The shock wave transdermal drug delivery hydrogel microneedle device according to claim 1, characterized in that: The hydrogel microneedle patch comprises: a backing layer and a microneedle array; The backing layer is a flexible cushion that can fit closely to the affected skin of the patient and the shock wave source, and is used to fill the gap between the affected skin of the patient and the shock wave source; The front side of the backing layer is provided with a plurality of microneedle arrays arranged at equal intervals, and the microneedle array is a rectangular array composed of a plurality of microneedles arranged at equal intervals.

3. The shock wave transdermal drug delivery hydrogel microneedle device according to claim 2, characterized in that: The backing layer is also provided with a plurality of bending regions, and the bending regions are arranged between adjacent microneedle arrays and are used for bending the hydrogel microneedle patch.

4. The shock wave transdermal drug delivery hydrogel microneedle device according to claim 2, characterized in that: The microneedle is cone-shaped and is disposed on the front side of the backing layer to pierce the epidermis of the skin to create a transdermal channel.

5. The shock wave transdermal drug delivery hydrogel microneedle device according to claim 4, characterized in that: The microneedle is provided with a plurality of tiny holes for further allowing the drug to penetrate into the dermis of the skin.

6. The shock wave transdermal drug delivery hydrogel microneedle device according to claim 1, characterized in that: The plastic film is provided with an easy-tear strip, which is arranged in the middle of the plastic film and is used to tear the plastic film to expose the back side of the hydrogel microneedle patch.

7. The shock wave transdermal drug delivery hydrogel microneedle device according to claim 1, characterized in that: The hydrogel microneedle assembly further comprises a protective film, which is arranged on the front side of the hydrogel microneedle patch to prevent the front side of the hydrogel microneedle patch from being contaminated.

8. The shock wave transdermal drug delivery hydrogel microneedle device according to claim 1, characterized in that: The hydrogel microneedle assembly also includes a sealing film, which is arranged on the back of the plastic film and connected to the plastic film at both ends to seal the exposed portion of the back of the hydrogel microneedle patch.

9. The shock wave transdermal drug delivery hydrogel microneedle device according to claim 8, characterized in that: One end of the closed film is provided with an easy-tear line, and the easy-tear line is arranged at the connection between the closed film and the plastic film, and is used to tear the closed film to expose the plastic film.

Citation Information

Cited By

  • Microwave controlled-release corrosion type microneedle emplastrum

    CN119818823A